Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients

CONCLUSIONS: This study analyzed the expression pattern of XRCC2 in gliomas and its relationship with prognosis using multiple datasets. This is the first study to show that XRCC2, a novel oncogene, is significantly overexpressed in glioma and can lead to poor prognosis in glioma patients. XRCC2 could serve as a new biomarker for glioma diagnosis, treatment, and prognosis evaluation, thus bringing new insight into the management of glioma.PMID:34051735 | DOI:10.1186/s10020-021-00316-0

Source: Molecular Medicine - May 30, 2021 Category: Molecular Biology Authors: Zhendong Liu Wang Zhang Xingbo Cheng Hongbo Wang Lu Bian Jialin Wang Zhibin Han Yanbiao Wang Xiaoyu Lian Binfeng Liu Zhishuai Ren Bo Zhang Zhenfeng Jiang Zhiguo Lin Yanzheng Gao Source Type: research